Detalles de la búsqueda
1.
Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
Cancer Immunol Immunother
; 67(10): 1519-1531, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30039427
2.
CAR T cells: driving the road from the laboratory to the clinic.
Immunol Rev
; 257(1): 91-106, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24329792
3.
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Cancer Immunol Immunother
; 66(11): 1425-1436, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28660319
4.
Exploiting natural killer group 2D receptors for CAR T-cell therapy.
Future Oncol
; 13(18): 1593-1605, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28613086
5.
Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model.
J Immunol
; 192(8): 3654-65, 2014 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24623129
6.
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.
Cancer Immunol Immunother
; 63(2): 133-45, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24190544
7.
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.
Haematologica
; 103(9): e424-e426, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29703727
8.
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Lancet Haematol
; 10(3): e191-e202, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36764323
9.
Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?
Breast Cancer Res
; 14(3): 106, 2012 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-22643384
10.
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
Cancer Immunol Immunother
; 61(7): 953-62, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22527245
11.
Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.
Cancer Immunol Immunother
; 61(7): 1005-18, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22127365
12.
The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.
J Immunol
; 184(12): 6938-49, 2010 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20483753
13.
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
J Immunol
; 184(4): 1885-96, 2010 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20089697
14.
Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy.
J Immunother
; 45(3): 150-161, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35191428
15.
Gene delivery of a mutant TGFß3 reduces markers of scar tissue formation after cutaneous wounding.
Mol Ther
; 18(12): 2104-11, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20736928
16.
Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction of mouse T cells with HIV-1 vectors.
J Gene Med
; 12(2): 129-36, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20033928
17.
Development of a flow cytometric co-immunoprecipitation technique for the study of multiple protein-protein interactions and its application to T-cell receptor analysis.
Cytometry A
; 77(4): 338-46, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20033991
18.
The integrated stress response promotes B7H6 expression.
J Mol Med (Berl)
; 98(1): 135-148, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838577
19.
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.
BioDrugs
; 33(5): 515-537, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31363930
20.
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Cancer Immunol Res
; 7(1): 100-112, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30396908